Knowledge Library
DDC 2023: Biophysical & Functional Characterization of Bifunctional Small Molecules Enables TPD Drug Discovery
Leverage our platform of biophysical methods to accelerate your research on targeted protein degradation. At DDC 2023, WuXi AppTec scientists...
Continue Reading
AACR 2023: Integrated platform enables KRAS-targeted drugs discovery
Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays...
Continue Reading
AACR 2023: A tailored platform enables BRAF-targeted drug discovery and precision medicine
In our latest AACR poster, WuXi AppTec scientists showcase the development of a tailored platform of patient-derived xenograft (PDX) models...
Continue Reading
Discovery Newsletter: April 2023
In this month’s newsletter, learn more about our comprehensive panel of CDK4/6 inhibitor-resistant breast cancer models and in vitro imaging...
Continue Reading
Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of...
Chronic HBV infection (CHB) is a major contributor to liver-related deaths worldwide. The ultimate endpoint of CHB treatment is sustained HBV...
Continue Reading
Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte models...
WuXi AppTec scientists recently contributed to a research study published in the journal Hepatology, characterizing the efficacy of prodrug DF-006...
Continue Reading
Optimization and Mechanistic Investigations of Novel Allosteric Activators of PKG1α
WuXi AppTec scientists recently contributed to a research article in the Journal of Medicinal Chemistry describing the optimization of a...
Continue Reading
Large-scale synthesis of a Notum inhibitor employing a modified Sakai reaction as the key step
WuXi AppTec scientists recently contributed to a research article in the Royal Society of Chemistry describing the large-scale synthesis of...
Continue Reading
